Carbamylation-derived products: bioactive compounds and potential biomarkers in chronic renal failure and atherosclerosis.
about
The optimal cutoff value of glycated hemoglobin for detection of diabetic retinopathyThe Role of Posttranslational Protein Modifications in Rheumatological Diseases: Focus on Rheumatoid ArthritisProtein carbamylation in chronic systolic heart failure: relationship with renal impairment and adverse long-term outcomes.Protein carbamylation in kidney disease: pathogenesis and clinical implicationsChronic increase of urea leads to carbamylated proteins accumulation in tissues in a mouse model of CKDCarbamylation of serum albumin as a risk factor for mortality in patients with kidney failure.Post-translational modifications of pancreatic fluid proteins collected via the endoscopic pancreatic function test (ePFT).Carbamylation of serum albumin and erythropoietin resistance in end stage kidney disease.Cyanate-Impaired Angiogenesis: Association With Poor Coronary Collateral Growth in Patients With Stable Angina and Chronic Total Occlusion.Carbamylated-oxidized LDL: proatherosclerotic effects on endothelial cells and macrophagesAutoantibodies to posttranslational modifications in rheumatoid arthritis.Proteomics of plaques and novel sources of potential biomarkers for atherosclerosis.The pathogenic potential of autoreactive antibodies in rheumatoid arthritis.Emerging role of post-translational modifications in chronic kidney disease and cardiovascular disease.Post-translational modifications in rheumatoid arthritis and atherosclerosis: Focus on citrullination and carbamylation.Carbamylation of vimentin is inducible by smoking and represents an independent autoantigen in rheumatoid arthritis.Changes in the conformational state of hemoglobin in hemodialysed patients with chronic renal failure.Longitudinal Changes in Protein Carbamylation and Mortality Risk after Initiation of HemodialysisAlkylation and Carbamylation Effects of Lomustine and Its Major Metabolites and MGMT Expression in Canine Cells.Prediction of carbamylated lysine sites based on the one-class k-nearest neighbor method.Effects of four different antihypertensive drugs on plasma metabolomic profiles in patients with essential hypertension.Nutritional therapy reduces protein carbamylation through urea lowering in chronic kidney disease.Mechanisms and consequences of carbamoylation.Quantification of carbamylated albumin in serum based on capillary electrophoresis.Homocitrulline: a new marker for differentiating acute from chronic renal failure.Myeloperoxidase derived oxidants damage artery wall proteins in an animal model of chronic kidney disease accelerated atherosclerosis.[Protein molecular aging: which role in physiopathology?]Alterations in conformational state of albumin in plasma in chronic hemodialyzed patients.Carbamylated Hemoglobin can Differentiate Acute Kidney Injury from Chronic Kidney Disease.
P2860
Q26859260-B4EEC1A1-A4E7-4C37-A7F8-33F14AD1F7C2Q28395318-8902BABE-DB34-430B-8BC6-7828A400AA04Q30429333-575ACA61-0018-41FA-8619-5478A5927464Q34403945-DE27FEA7-5A86-43EC-BC26-39DCFABDDF89Q35064221-35C81E11-CDB4-40ED-A750-5B3B3C5ABBBBQ36971450-6389297F-B931-48D3-9B60-CDAF00D76B3CQ37064216-7E37F451-CB9F-4E1C-87C4-36CE97423338Q37280857-CA347C3F-4842-46DF-B065-D1E95D0B59ACQ37556270-2A33B5F9-A6E6-4B96-ADB2-F56A7F2112BFQ37693244-B62E0F7B-4092-49D9-B398-08C7E6606FB8Q37693939-07E9AA01-741E-44FD-B87D-1E97647A2313Q38106664-5EFE3978-6C36-44BB-AEBC-DD64CCEE3F8BQ38206946-826690C2-52D7-4995-8B97-0C2ADD6ADDB1Q38415749-5A7108EE-6864-4668-B93D-10149C7545F6Q38967382-381CE6F5-A020-47FB-ACEE-DF81433C23D9Q41146137-CDCEC4E8-9614-4843-894F-E88B2D0F2D77Q41992654-C3815880-8E1D-42E0-9664-2E4A249B4970Q42110772-03BAC777-84FF-4AD3-9D3D-71CE65E95E53Q43169766-F6658C28-DE6D-4F17-B92D-62DDF142A3BAQ44845081-7D595563-E611-4F65-8FFC-8F884BDBA144Q47168939-18BE595E-A2B8-41A6-9C71-447E2C919D8FQ47676591-12F4CB58-ED05-48AA-A8E7-6FD4C83E5314Q48010750-85F74D14-6847-4F9F-B204-C28E4240A1DFQ48360830-89F48B33-03A3-4AC4-867E-3C40AD858762Q50541406-15215A01-5E03-42E8-B670-0D4703013896Q52629638-5B78C6B0-9E77-4AA1-BEEE-8268697C1826Q53520142-1EA5A81E-6C1F-412B-9308-BA2B7FE5B494Q55379976-719F7253-43B2-440C-8FA1-B1A73FBEF388Q55381637-375154E2-B823-4A9F-8475-7E01C99FE5C4
P2860
Carbamylation-derived products: bioactive compounds and potential biomarkers in chronic renal failure and atherosclerosis.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Carbamylation-derived products ...... l failure and atherosclerosis.
@ast
Carbamylation-derived products ...... l failure and atherosclerosis.
@en
Carbamylation-derived products ...... l failure and atherosclerosis.
@nl
type
label
Carbamylation-derived products ...... l failure and atherosclerosis.
@ast
Carbamylation-derived products ...... l failure and atherosclerosis.
@en
Carbamylation-derived products ...... l failure and atherosclerosis.
@nl
prefLabel
Carbamylation-derived products ...... l failure and atherosclerosis.
@ast
Carbamylation-derived products ...... l failure and atherosclerosis.
@en
Carbamylation-derived products ...... l failure and atherosclerosis.
@nl
P2093
P1433
P1476
Carbamylation-derived products ...... l failure and atherosclerosis.
@en
P2093
Christine Pietrement
Philippe Gillery
Stéphane Jaisson
P304
P356
10.1373/CLINCHEM.2011.163188
P407
P577
2011-07-18T00:00:00Z